Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2024:2849:185-202.
doi: 10.1007/7651_2023_510.

Human-Induced Pluripotent Stem Cell‒Derived Keratinocytes, as Therapeutic Option in Vitiligo

Affiliations

Human-Induced Pluripotent Stem Cell‒Derived Keratinocytes, as Therapeutic Option in Vitiligo

Babak Arjmand et al. Methods Mol Biol. 2024.

Abstract

Vitiligo is a skin condition affecting 1% of the global population, causing non-scaly, chalky-white macules on the skin and hair. It is caused by the pathologic destruction of melanocytes, which produce melanin. Research has focused on the abnormalities of melanocytes and their interaction with neighboring keratinocytes. Current treatments are mainly immunosuppressive drugs and UV radiation, which are scarce and ineffective. To treat vitiligo, regenerative medicine techniques, such as cell-based and cell-free methods, are recommended. Keratinocyte cell transplantation has shown promising results in treating vitiligo. Moreover, studies suggest individualized therapy for diseases can be provided by reprogramming somatic cells into induced pluripotent stem cells. On the other hand, differentiation into particular cell types is a key component of induced pluripotent stem cells-based treatment. In this chapter, the differentiation and validation of human induced pluripotent stem cells into a keratinocyte as a therapeutic option in vitiligo will be discussed.

Keywords: Cell therapy; Differentiation; Induced pluripotent stem cells; Keratinocyte; Regenerative medicine; Vitiligo.

PubMed Disclaimer

Similar articles

Cited by

References

    1. Aghayan HR, Goodarzi P, Arjmand B (2015) GMP-compliant human adipose tissue-derived mesenchymal stem cells for cellular therapy. Methods Mol Biol 1283:93–107. https://doi.org/10.1007/7651_2014_112 - DOI - PubMed
    1. Aghayan HR, Payab M, Mohamadi-Jahani F et al (2021) GMP-compliant production of human placenta-derived mesenchymal stem cells. Methods Mol Biol 2286:213–225. https://doi.org/10.1007/7651_2020_282 - DOI - PubMed
    1. Aghayan HR, Hosseini MS, Gholami M et al (2022) Mesenchymal stem cells’ seeded amniotic membrane as a tissue-engineered dressing for wound healing. Drug Deliv Transl Res:1–12
    1. Ali G, Abdelalim EM (2022) Directed differentiation of human pluripotent stem cells into epidermal keratinocyte-like cells. STAR Protoc 3(3):101613. https://doi.org/10.1016/j.xpro.2022.101613 - DOI - PubMed - PMC
    1. Allam M, Riad H (2013) (2013) Concise review of recent studies in vitiligo. Qatar Med J 2:1–19. https://doi.org/10.5339/qmj.2013.10 - DOI

LinkOut - more resources